title: For the RECORD, we should SWITCH our treatment AXIS before the SUNRISES and TARGET the BEST treatments before INTORSECTing with a GOLD METEOR: a tale of sequences and combinations.
authors: Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: Dae Y
authors: DY
authors: Kim
authors: Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: JAKaram@mdanderson.org.
authors: Jose A
authors: JA
authors: Karam
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D042461:Vascular Endothelial Growth Factor A; D040262:Receptors, Vascular Endothelial Growth Factor; D058570:TOR Serine-Threonine Kinases